Deals and Financings

• Beijing's BeiGene will receive a $150 million termination fee as Celgene ends its $1.4 billion co-development partnership for BeiGene's PD-1 candidate; 
• Akeso Pharma of Zhongshan formed a $100 million JV with a Sino Biopharma subsidiary to commercialize Akeso's clinical-stage PD-1 mAb; 
• CASI Pharma, a US-China company, will invest $11.6 million in Tianjin's Juventas Cell Therapy for global rights to an autologous CD19 T-cell therapy; 
• BeiGene and US-based SpringWorks joined to form MapKure, which will run non-Asia clinical trials of BeiGene's B-RAF inhibitor;
• Jiangsu Hengrui in-licensed greater China rights to a chronic yeast infection treatment from Mycovia Pharma of Durham, North Carolina;

Trials and Approvals

• Chi-Med announced an early end to its Phase III surufatinib trial after interim data showed the candidate met its primary progression-free survival endpoint; 
• Suzhou Innovent said its BCMA CAR-T candidate produced a 100% objective response rate in patients with relapsed/refractory multiple myeloma; 
• Gracell Biotechnologies of Suzhou reported its FasT CAR-19 therapy produced a 100% response rate in 16 B-cell leukemia patients;
• Shanghai Henlius, a Fosun subsidiary, announced the EMA will review its Marketing Authorization Application for a Herceptin biosimilar; 
• Cellular Biomedicine, a New York-Shanghai company, started a China Phase I trial of its CD20 CAR-T candidate in relapsed lymphoma patients;
• CARsgen Therapeutics of Shanghai was OK'd to start US trials of its fully human BCMA-CAR-T therapy in patients with multiple myeloma;

Company News

• dMed Biopharma, a Shanghai clinical CRO, opened a Washington office to help China biopharmas complete US regulatory filings, a growing market.